April 20, 2017
4 min read
Save

More than 50% of patients with tree nut-allergy passed an oral food challenge

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Despite exhibiting skin or blood test sensitivity to peanuts and tree nuts, more than 50% of patients with a documented allergy to an individual nut passed oral food challenges consisting of additional nuts, according to data published in Annals of Allergy, Asthma and Immunology.

“Patients allergic to a particular tree nut often demonstrate co-sensitization to other tree nuts. In patients with peanut allergy, tree nut co-sensitization can occur in up to 86% of patients, although only 34% might display clinical reactivity — for example, symptom development after ingestion,” Christopher Couch, MD, from the division of allergy and clinical immunology at The University of Michigan School of Medicine and Allergy Asthma Clinic, and colleagues wrote. “Furthermore, many providers instruct children with peanut allergy to avoid tree nuts because of tree nut sensitization, despite no history of any tree nut reaction or low or absent sensitization.”

Christopher Couch

To assess the connection between oral food challenge (OFC) outcomes and tree nut sensitization, the researchers analyzed open tree nut OFCs performed at a referral center from 2007 to 2015. The results of the OFCs were compared with skin prick test (SPT) wheal size, food-specific immunoglobin E (sIgE), peanut co-allergy and tree nut sensitization only vs. tree nut allergy with sensitization to other tree nuts. A delayed OFC occurred more than 1 year after the time of an sIgE level below 2kUA/L.

The researchers recorded 156 tree nut OFCs performed in 109 patients, including 54 almond, 28 cashew, 27 walnut, 18 hazelnut, 14 pecan, 13 pistachio and two brazil nut. Eighty-six percent of the patients passed, with a 76% passing rate for those with a history of tree nut allergy. These individuals were challenged with a tree nut to which they were sensitized. Those who had tree nut sensitization only had a 91% passing rate.

“Too often, people are told they’re allergic to tree nuts based on a blood or skin prick test,” Couch said in a press release. “They take the results at face value and stop eating all tree nuts when they might not actually be allergic. [In this study] despite showing a sensitivity to the additional tree nuts, more than 50% of those tested had no reaction in an oral food challenge.”

Individuals who had a tree nut sIgE less than 2 kUA/L had an 89% passing rate, and those who had sIgE levels of at least 2 kUA/L had a passing rate of 69%. Out of all challenges performed, 44 occurred in patients with peanut allergy and tree nut co-sensitization; 96% of these patients passed the tree nut OFC. When challenges were compared with SPCs, 61% of those who had a tree nut SPT wheal size of at least 3 mm passed. Those who failed had a larger mean wheal size (9 mm) compared with those who passed (4.8mm).

“Previous studies suggested people with a tree nut allergy, as well as those with a peanut allergy, were at risk of being allergic to multiple tree nuts,” researcher Matthew Greenhawt, MD, chair of the ACAAI Food Allergy Committee, said in a press release “We found even a large-sized skin test or elevated blood allergy test is not enough by itself to accurately diagnose a tree nut allergy if the person has never eaten that nut. Tree nut allergy should only be diagnosed if there is both a positive test and a history of developing symptoms after eating that tree nut.” by Katherine Bortz

Disclosure: Dr. Greenhawt is an expert panel member of the Guidelines for Peanut Allergy Prevention sponsored by the National Institute of Allergy and Infectious Diseases; has served as a consultant for the Canadian Transportation Agency and Aimmune Therapeutics; is a member of physician and medical advisory boards for Aimmune, Nutricia, Kaleo Pharmaceutical, Nestle, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honoraria for lectures from Thermo Fisher, ReachMD, and the Kentucky, Pennsylvania, Aspen, and New York allergy societies, the American College of Allergy, Asthma, and Immunology, the European Academy of Allergy and Clinical Immunology, and the UCLA-Harbor Medical Center; and is a member of the Joint Task Force on Allergy Practice Parameters. He has also received support from the National Center for Advancing Translational Sciences. C. Couch and T. Franxman report no relevant financial disclosures or conflicts of interest.